Atlas›Domain IX · Biomedical, neuro & digital›Guide 104
Guide IX-104

Ketogenic and metabolic therapy

Christopher M. Palmer2022
A 31 · L 64 · M 511 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the team-based practice described in the modified Delphi consensus by Ede, Bernstein, Calabrese, Campbell, Laurent, Palmer, Sethi and Zupec-Kania (Frontiers in Nutrition, 2026), supplemented by the safety and practical advice in Rog et al. (Journal of Clinical Medicine, 2024) and the delivery descriptions of two pilot studies (Sethi et al., Psychiatry Research, 2024; Needham et al., BJPsych Open, 2023). This guide is written for the psychotherapist working alongside the medical and nutrition team; it contains no diet plan, no macronutrient ratios, no ketone, calorie or weight targets and no supplement doses.

What it is. Ketogenic metabolic therapy (KMT) is a medically supervised dietary treatment, adapted from its use in epilepsy, that shifts the body towards burning fat and producing ketones. In psychiatry it is being studied as an adjunct to standard treatment for serious mental illness (schizophrenia, bipolar disorder, major depression and others). The consensus panel is explicit that it is added to first-line treatment, not used instead of it, and should not be used on its own for acute, unstable or dangerous presentations such as new or worsening mania or psychosis, active suicidal ideation or severe agitation. [source: Ede et al. 2026]

Core idea of change (attributed). Christopher M. Palmer, a Harvard and McLean Hospital psychiatrist, argues in Brain Energy (BenBella, 2022) that "Mental disorders are metabolic disorders of the brain" (publisher's description); on this view, changing brain energy metabolism could change symptoms. Stanford's report on the Sethi pilot likewise describes improved brain energy metabolism as a hypothesis, with multiple mechanisms likely. These are claims and hypotheses, not established mechanisms. [source: BenBella Books page; Stanford Medicine News 2024]

Evidence status. Small and early. The Stanford pilot (21 adults with schizophrenia or bipolar disorder on antipsychotics with at least one metabolic abnormality, four months, no control group) reported metabolic improvements and improvement on clinician-rated global impression; it was described as exploratory, a search for signals to guide larger studies. The Scottish bipolar pilot (single group, euthymic adults) concluded only that a diet study was feasible and that a randomised trial is warranted. A 2024 narrative review rated the human evidence as mainly pilot studies and case reports of weak quality; the 2026 consensus notes there are no randomised trials in serious mood and psychotic illness and that the consensus is expert opinion, with disclosed financial or advisory ties among many panellists. Stanford's pilot was funded in part by the Baszucki Group Research Fund. [source: Stanford Medicine News 2024; Needham et al. 2023; Rog et al. 2024; Ede et al. 2026]

Who delivers it and regulatory status. Diet design and supervision belong to a prescribing clinician and a nutrition professional (dietitian, licensed nutritionist, or a prescriber or health coach trained in KMT); the consensus sets this as the minimum team and adds that a therapist, nurse or health coach may be part of it. The standard of an "expert KMT practitioner" is not yet defined. Rog et al. recommend initiation in hospital with a physician and dietitian. KMT is a dietary treatment rather than a licensed medicine or device, so, as of October 2026 per the sources cited, it carries no product approval for psychiatric indications; whether any national guideline (e.g. NICE, APA) recommends it for mental illness is [uncertain: not verified] and none of the sources cited here reports such a recommendation. [source: Ede et al. 2026; Rog et al. 2024]

The psychotherapist's role is not to design or supervise the diet but to: respond thoughtfully when a client raises it; screen for eating-disorder risk and pass concerns on; route the client to the medical team and dietitian; support informed decision-making; watch mood, sleep, psychotic symptoms and suicide risk closely, especially early on; support adherence and coping without becoming the diet's enforcer; and make sure no psychiatric medicine is stopped or changed outside the prescriber's care. [synthesis, based on Ede et al. 2026 and Rog et al. 2024]

2. Framework

The sources describe a medically led course rather than a psychotherapy protocol. The phases below organise their content around the therapist's tasks. [synthesis; content sourced as tagged]

Phase A: Client raises interest (therapy session). Goal: explore motives and expectations, check for eating-disorder history and current crisis, give balanced information, and refer to the client's prescriber. Typically 1–2 sessions within ongoing therapy. Move on when the client has a medical appointment and understands the treatment is adjunctive and supervised. [synthesis]

Phase B: Medical and nutrition assessment (medical team). A detailed medical and psychiatric history must always be taken. The team checks absolute contraindications (the consensus lists liver failure, acute pancreatitis, porphyria, severe inherited lipid disorders per one source, SGLT2 inhibitor use, and underweight anorexia nervosa) and relative ones (diabetes and its medicines, antihypertensive medicines, cardiovascular and cerebrovascular disease, kidney disease, past or present kidney stones, osteoporosis, inadequate social support). Baseline blood tests are taken. Rog et al. add that it should not be recommended in pregnancy or when planning pregnancy, and recommend cardiac assessment given raised cardiovascular risk in serious mental illness. The therapist contributes information (with consent) on eating history, current risk, support and motivation. Move on only when the medical team has decided the client is a candidate. [source: Ede et al. 2026; Rog et al. 2024]

Phase C: Initiation and early adaptation (first weeks). Goal: start safely. Rog et al. recommend initiation in hospital conditions; the consensus notes people with less support may do better in intensive outpatient, residential or inpatient settings. The Scottish pilot gave weekly remote dietitian contact, a research psychiatrist for mental-state concerns, and continued routine medical care. Early side effects are common (the "keto flu": headache, nausea, fatigue, weakness, gastrointestinal upset), usually improving within weeks. Mood and other psychiatric symptoms may emerge or worsen, "more frequently during the first few weeks". Therapy: more frequent check-ins, explicit early-warning plan, rapid reporting to the team. [source: Rog et al. 2024; Needham et al. 2023; Ede et al. 2026]

Phase D: Maintenance (weeks to months). Goal: sustain the plan the team set, with regular laboratory and clinical monitoring, and avoid judging benefit too early (benefits may take weeks to months). The Stanford pilot ran four months with a health coach and regular objective adherence checks. Therapy: integrate the change into ongoing psychotherapy, address barriers, track mood and risk. [source: Ede et al. 2026; Stanford Medicine News 2024]

Phase E: Stopping, lapse or long-term continuation. The consensus says KMT "can be readily discontinued" if safety concerns arise, mitigation fails or symptoms are too distressing, but safe discontinuation practices for mental health are not yet defined; it recommends a personalised contingency plan (more support, temporary medication, or both) in case ketosis is interrupted and symptoms return. In the Scottish pilot one participant had a hypomanic episode within a week of stopping. Therapy: treat stopping and lapses as a period of heightened monitoring, not failure. [source: Ede et al. 2026; Needham et al. 2023]

Movement between medical phases is decided by the prescriber and nutrition professional, never by the therapist or client alone. [source: Ede et al. 2026]

3. Guiding principles

  • Adjunct, never replacement. Practical meaning: you never frame the diet as an alternative to medication or therapy. [source: Ede et al. 2026]
  • Medical supervision is non-negotiable. Practical meaning: if a client is starting on their own, your first move is a referral to their prescriber. [source: Ede et al. 2026; Rog et al. 2024]
  • Medicines are the prescriber's business. Psychiatric, diabetes and blood-pressure medicines may need prescriber adjustment during KMT. Practical meaning: you never suggest reducing, stopping or changing any medicine; you pass on what you hear. [source: Ede et al. 2026]
  • Screen for eating disorders first. Underweight anorexia nervosa is viewed as an absolute contraindication by the consensus authors; strict medically prescribed diets have been associated with disordered eating in other conditions. Practical meaning: ask about restriction, bingeing, purging and weight/shape preoccupation before engaging with any diet plan. [source: Ede et al. 2026; Eating Disorders Review 2000 summary of Chrisler and Antisdel]
  • Not for acute instability. Practical meaning: active suicidality, new mania or psychosis or severe agitation is a reason to prioritise crisis care, not diet change. [source: Ede et al. 2026]
  • Expect early turbulence. Practical meaning: increase contact in the first weeks and agree in advance what gets reported and to whom. [source: Ede et al. 2026]
  • Rule out physical causes of new symptoms. Dehydration, electrolyte imbalance, low blood pressure and low blood sugar should be checked when symptoms appear. Practical meaning: new anxiety, low mood, irritability or poor concentration during KMT goes to the medical team, not only into a psychological formulation. [source: Ede et al. 2026]
  • Honest evidence talk. Practical meaning: describe the research as small and early, attribute the brain-energy theory to its proponents, and avoid promising remission. [source: Rog et al. 2024; Ede et al. 2026]
  • Autonomy and shared decision-making. Practical meaning: you neither push nor forbid; you help the client weigh options with their team. [synthesis]
  • Support, not policing. Practical meaning: you help with motivation and problem-solving, but you do not monitor food intake or ketones; that is the nutrition team's role. [synthesis; Rog et al. 2024 recommends motivational interviewing and CBT to support adherence]
  • Work within your competence and the team. Practical meaning: share information with consent, document, and keep one clear line to the prescriber. [synthesis]

4. Intervention inventory

Part A describes how the medical and nutrition team delivers KMT, at a descriptive level only, so you can talk about it accurately. Part B is the psychotherapist's own work.

A1. How KMT is delivered (descriptive, for the therapist's understanding)

  • Purpose: to know what your client will experience and who is responsible for what.
  • Steps (as sources describe them): (1) detailed medical and psychiatric history and contraindication check; (2) baseline tests — the consensus lists a full blood count, comprehensive metabolic panel, fasting lipids, fasting insulin, vitamin B12, vitamin D and a carnitine panel; Rog et al. add urinalysis and kidney function for stone risk and liver tests plus cardiac assessment; (3) an individualised dietary prescription designed by a dietitian, licensed nutritionist or trained prescriber or coach, tailored to needs, preferences and long-term sustainability; (4) structured support — in the Scottish pilot, weekly remote dietitian contact, fidelity checklists informed by the COM-B behaviour-change framework and access to a research psychiatrist; in the Stanford pilot, cookbooks, meal ideas, a health coach and weekly objective adherence checks, with participants continuing their antipsychotics; (5) regular repeat laboratory monitoring and tracking of metabolic markers; (6) prescriber-managed adjustments of diabetes, blood-pressure and psychiatric medicines as needed; (7) a contingency plan for interruption, and a supervised decision about continuing or stopping. Hydration and electrolytes are emphasised throughout. [source: Ede et al. 2026; Rog et al. 2024; Needham et al. 2023; Stanford Medicine News 2024]
  • Example language (illustrative): "In the studies, people did this with a doctor and a dietitian checking blood tests and medicines regularly. My part is the psychological side: how you're feeling, how it fits your life, and making sure your team hears quickly about any change in your mood."
  • Watch for: a client describing a plan with no prescriber or dietitian involved, no baseline blood tests, or a coach who is advising on medicines; any of these is a cue for A2 and B3.

A2. Documented risks and required monitoring (descriptive)

  • Purpose: to recognise warning signs and pass them to the team; never to manage them yourself.
  • What sources state:
    • SGLT2 inhibitors (a diabetes medicine class): listed by the consensus as an absolute contraindication because of euglycaemic ketoacidosis risk. In the Scottish bipolar pilot, a participant with type 2 diabetes taking an SGLT2 inhibitor and another diabetes medicine developed euglycaemic ketoacidosis on day three, was hospitalised, recovered and withdrew; the treating team attributed it likely to the combination of the medicine and starting the diet. [source: Ede et al. 2026; Needham et al. 2023]
    • Other diabetes medicines and insulin: blood-sugar medicines "often require frequent and potentially early adjustments" by a prescriber; low blood sugar occurred in several pilot participants. Rog et al. state the diet is not recommended with insulin-treated diabetes or recurrent severe hypoglycaemia. [source: Ede et al. 2026; Needham et al. 2023; Rog et al. 2024]
    • Blood-pressure medicines, including diuretics: need frequent prescriber adjustment. [source: Ede et al. 2026]
    • Lithium: the KMT sources cited here do not set out a specific lithium interaction [uncertain]. The US lithium label (2018 version) carries a boxed warning that toxicity is closely related to serum concentrations and can occur close to therapeutic levels; it names changes in electrolytes (especially sodium and potassium) and dehydration from prolonged sweating, diarrhoea or fever as risk factors, advises patients to keep a normal diet including salt and adequate fluids, and lists diarrhoea, vomiting, tremor, poor coordination, drowsiness, abnormal heart rhythm and muscle weakness as signs needing prompt contact with the prescriber. Serum levels are to be monitored after changes such as new medicines, illness or significant changes in activity. Because KMT changes fluid and electrolyte balance and early adaptation can bring vomiting or diarrhoea, any client on lithium needs their prescriber involved before and during KMT. [source: FDA lithium label 2018; the link to KMT is synthesis]
    • Valproate: named by the consensus as a risk factor for acquired carnitine deficiency, calling for closer monitoring; carnitine management did not reach consensus. [source: Ede et al. 2026]
    • Lipids: LDL cholesterol can rise with carbohydrate restriction; caution with existing dyslipidaemia; lipid problems may be more likely with atypical antipsychotics. Lipid changes occurred in nine Scottish pilot participants. [source: Ede et al. 2026; Rog et al. 2024; Needham et al. 2023]
    • Kidney stones: past or present stones are a relative contraindication; long-term risks listed by Rog et al. include stones, raised lipids, cardiovascular complications, reduced bone density and menstrual disorders. [source: Ede et al. 2026; Rog et al. 2024]
    • Constipation: common with low fibre and can be severe when combined with anticholinergic medicines such as clozapine, olanzapine, phenothiazines and tricyclics. [source: Rog et al. 2024]
    • Nutritional deficiencies, dehydration and electrolyte disturbance with unbalanced versions. [source: Rog et al. 2024]
    • Pregnancy: not recommended in pregnancy or when planning pregnancy. [source: Rog et al. 2024]
    • Psychiatric: mood or other symptoms (depression, hypomania, mania, psychosis, anxiety, insomnia, irritability, poor concentration) may emerge or worsen, more often in the first weeks; one hypomanic episode after stopping and one depressive episode during the diet were reported in the Scottish pilot; one participant there needed a medication change by their psychiatrist after a month of elevated mood. [source: Ede et al. 2026; Needham et al. 2023]
  • Steps [synthesis]: (1) With consent, ask the team for the client's medicine list and the monitoring agreed. (2) At each session, ask briefly about the warning signs above. (3) Pass any sign to the prescriber or team the same day; advise urgent or emergency care if severe. (4) Record what you passed on and to whom; never adjust the diet or any medicine yourself.
  • Example language (illustrative): "Because you take lithium, your psychiatrist needs to be part of this from the start. Changes in fluids and salt can affect lithium levels, and if you get vomiting, diarrhoea, a new tremor or feel unsteady, that's a call to them the same day."
  • Watch for: the signs above; new or worsened mood or psychotic symptoms; dizziness, faintness, confusion or severe fatigue (possible dehydration, low blood pressure or low blood sugar). Route all of these to the prescriber or, if severe, urgent care. [source: Ede et al. 2026; FDA lithium label 2018]

B1. Responding when a client wants to try it

  • Purpose: keep the alliance, respect autonomy and steer interest into safe, supervised channels.
  • When to use: a client mentions Brain Energy, online communities, a podcast, a friend's story, or says they have started already.
  • Steps: (1) ask with curiosity what they have read and what they hope will change; (2) ask whether they have started, and how (on their own, with a coach, with their doctor); (3) acknowledge the reasons (side effects, weight gain, poor response to medication are common motives and are among the groups the consensus says may be considered); (4) give balanced information: small early studies, done under medical supervision, as an add-on; (5) run the eating-disorder screen (B2) and a brief current-risk check; (6) recommend a conversation with the prescriber and a dietitian before any change, and offer to help prepare for it; (7) agree that medicines stay as they are until the prescriber says otherwise; (8) record the conversation. [synthesis; candidacy and evidence content from Ede et al. 2026 and Rog et al. 2024]
  • Example language (illustrative): "It makes sense that you'd want something that might help with the weight gain and the low energy. The research is promising but early, and every study did it with a medical team watching blood tests and medicines. Would you be willing to bring it to Dr X first? We could plan together what you'd ask."
  • Watch for: idealisation ("this will cure me"), hope of getting off medication, secrecy from the prescriber, a strong weight-loss focus, or pressure from family or online groups. Working: the client books a medical review and talks openly about the plan.

B2. Eating-disorder screening and caution

  • Purpose: prevent a restrictive medical diet from triggering or masking an eating disorder.
  • When to use: before any engagement with KMT, and repeatedly during it.
  • Steps: (1) ask about past or present restriction, bingeing, purging, compensatory exercise, laxative misuse, fear of particular foods, and how much weight and shape drive self-worth; (2) ask about past diagnosis or treatment for an eating disorder and about the lowest and current weight trend only as the client is comfortable, without setting or discussing targets; (3) where your service uses a validated eating-disorder screening questionnaire, use it as licensed; do not improvise items; (4) if there is any current eating disorder or significant history, tell the client plainly that this needs specialist medical and eating-disorder input before any restrictive diet, and inform the prescriber with consent; (5) during KMT, revisit these questions at regular sessions. [synthesis; the consensus authors "currently view underweight anorexia nervosa as an absolute contraindication" and note use after weight restoration is only being explored (Ede et al. 2026); disordered eating has been associated with strict medically required diets in diabetes and phenylketonuria (Eating Disorders Review 2000 summary of Chrisler and Antisdel); Rog et al. 2024 list binge eating and food cravings among adherence barriers]
  • Example language (illustrative): "Before we go further, can I ask about your history with food? Some people find that strict food rules start to take over, and if that's ever happened to you, your team needs to know so they can keep you safe."
  • Watch for: rigid rules spreading beyond the prescribed plan, guilt or self-punishment after "breaking" it, hiding food, bingeing after restriction, weight loss becoming the main goal, anxiety around meals, social withdrawal around eating, menstrual changes. Working: the client can talk openly about lapses without shame, and food stays in proportion to the rest of life.

B3. Referral and collaborative care

  • Purpose: connect the client to the prescriber and a nutrition professional and keep the team informed.
  • When to use: any serious interest in KMT; any self-started diet; any warning sign in A2.
  • Steps: (1) obtain consent to contact the prescriber or GP; (2) send a brief note: client's interest or current diet, relevant psychiatric history, eating-disorder screen findings, current risk, support available; (3) ask the team to confirm who leads medical monitoring and who to contact with concerns, including out of hours; (4) agree what you will report (mood shifts, sleep loss, psychotic symptoms, suicidal thoughts, disordered-eating signs, reported physical symptoms, any talk of stopping medicines); (5) if no KMT-trained team is available locally, tell the client honestly and do not fill the gap yourself. [synthesis; team composition and the undefined standard of expert practitioners from Ede et al. 2026; scarcity of dietitians in mental health services noted by Rog et al. 2024]
  • Example language (illustrative): "With your permission I'll write to Dr X so we're all working from the same picture, and so I know who to call if your mood changes while you're doing this."
  • Watch for: fragmented care (coach, online group and prescriber not talking), the client asking you to keep the diet from the prescriber. Working: one named medical lead and a clear reporting route.

B4. Psychoeducation and shared decision-making

  • Purpose: help the client make an informed choice with the team.
  • Steps: (1) explain what KMT is and that it is studied as an add-on; (2) describe the evidence honestly (small pilots, no randomised trials in serious mood and psychotic illness yet); (3) attribute the brain-energy theory to its proponents; (4) outline what supervision involves (tests, regular contact, medicine reviews) and the common early effects; (5) name the practical demands (shopping, cooking, social eating, cost) and the support needed; (6) list the client's questions for the team; (7) respect a decision either way. [source: Ede et al. 2026; Rog et al. 2024; Stanford Medicine News 2024; steps 5–7 synthesis]
  • Example language (illustrative): "Here's what we know: a few small studies, people supported closely, some encouraging changes, and no large controlled trials yet. Here's what we don't know: whether it would help you, and how long benefits last. Let's write down what you want to ask your psychiatrist."
  • Watch for: the client hearing only the hopeful part, or feeling judged for interest. Working: the client can summarise both possible benefits and risks in their own words.

B5. Medication-safety and adherence conversations

  • Purpose: prevent unsupervised stopping or changing of medicines, which some clients hope the diet will allow.
  • When to use: any hint of wanting to reduce, stop or skip medicines, or reports that a coach or online source suggested it.
  • Steps: (1) explore the wish without arguing (side effects, identity, stigma, hope); (2) state clearly that medicine changes are the prescriber's decision and that the consensus treats KMT as an addition to standard treatment; (3) note that case reports describe medication reductions, sometimes without supervision, which is exactly what to avoid; (4) encourage the client to raise side effects and hopes with the prescriber; (5) inform the prescriber with consent; (6) if the client has already stopped a medicine, treat this as a priority for prompt medical review and heighten risk monitoring. [source: Ede et al. 2026; Rog et al. 2024 for case reports; steps 1, 4–6 synthesis]
  • Example language (illustrative): "I hear how much you'd like to be on fewer tablets. That's a real goal to take to Dr X. Changing them on your own, especially while your diet is also changing, could be risky, so let's get that conversation booked."
  • Watch for: missed doses, "I feel so good I don't need them", new elevated mood, returning psychotic symptoms. Working: the client discusses medicines openly with their prescriber.

B6. Monitoring mood and risk; early-warning and safety plan

  • Purpose: catch emerging or worsening symptoms early, especially in the first weeks and around stopping.
  • Steps: (1) before starting, agree a written early-warning plan: the client's personal relapse signs, the symptoms the consensus lists (depression, hypomania, mania, psychosis, anxiety, insomnia, irritability, poor concentration) and who to call; (2) increase session frequency or add brief check-ins during the first weeks [synthesis]; (3) at each contact, ask about sleep, mood, energy, unusual experiences, suicidal thoughts and physical symptoms; (4) remember that physical causes (dehydration, electrolyte imbalance, low blood pressure, low blood sugar) should be checked by the team when new symptoms appear; (5) use standard suicide risk assessment and an up-to-date safety plan; active suicidal ideation, new mania or psychosis or severe agitation is a crisis to manage through usual pathways, and the consensus advises against KMT as a standalone treatment in these states; (6) repeat heightened monitoring after any lapse or stop. [source: Ede et al. 2026; Needham et al. 2023; steps 2, 6 partly synthesis]
  • Example language (illustrative): "Mood changes can happen more in the first few weeks, so let's agree now: if you're sleeping much less, feeling unusually driven or very low, you'll call the team that day and let me know."
  • Watch for: reduced need for sleep and rising energy misread as "the diet working"; low mood or irritability dismissed as "keto flu"; hopelessness after lapses. Working: changes are reported early and reviewed medically.

B7. Supporting adherence and behaviour change (without policing)

  • Purpose: help the client follow the plan their team set, if they choose to, and cope with its demands.
  • Steps: (1) use motivational interviewing to explore and strengthen the client's own reasons, and to respect ambivalence; (2) use CBT problem-solving for barriers named in the literature: impulsivity, apathy, low appetite, cravings, binge eating, appetite increases from medicines, and the practical load of shopping and cooking; (3) plan for social situations, travel and stress; (4) build support (family, carers, peer groups) where the client wishes; (5) refer dietary questions to the nutrition professional rather than answering them; (6) frame lapses as information. [source: Rog et al. 2024 recommends MI and CBT, problem-solving and side-effect management; COM-B fidelity support in Needham et al. 2023; steps 3–6 synthesis]
  • Example language (illustrative): "On a scale of 0 to 10, how important is this to you right now? What makes it a 6 and not a 3? … What gets in the way most on the hard days?"
  • Watch for: the client reporting food or ketone numbers to you as if for approval (redirect to the dietitian), shame-driven secrecy, all-or-nothing thinking. Working: the client problem-solves flexibly and stays engaged with the team.

B8. Lapses, stopping and continuing therapy afterwards

  • Purpose: keep the client safe and engaged when the diet is interrupted, stopped or continued long term.
  • Steps: (1) before starting, help the client know the team's contingency plan (the consensus recommends a personalised plan with more support, temporary medication, or both, if ketosis is interrupted and symptoms return); (2) if the client wants to stop, support the decision and ensure the team knows, since safe discontinuation practice for mental health is not defined; (3) monitor closely after stopping (a hypomanic episode after stopping was reported in one pilot); (4) process disappointment if the hoped-for change did not happen, and guard against self-blame; (5) continue psychotherapy for the original problems throughout and after. [source: Ede et al. 2026; Needham et al. 2023; steps 4–5 synthesis]
  • Example language (illustrative): "Stopping is a reasonable choice and it doesn't mean you failed. Let's make sure your team knows, and let's keep a close eye on sleep and mood over the next couple of weeks."
  • Watch for: mood change after stopping, rebound eating with guilt, abandonment of all treatment. Working: a planned transition with continued care.

B9. Clients who have started on their own

  • Purpose: reduce risk when KMT was started from a book, online community or app without supervision.
  • Steps: (1) ask non-judgementally what they are doing and since when; (2) check for urgent warning signs (A2), particularly in clients on lithium, valproate, SGLT2 inhibitors, insulin or other diabetes medicines, or blood-pressure medicines, and in pregnancy; (3) screen for disordered eating (B2) and current risk (B6); (4) urge prompt contact with the prescriber, and with consent contact them yourself; (5) do not advise on how to change, continue or stop the diet; leave that to the medical team. [source: contraindications and medication cautions from Ede et al. 2026, Rog et al. 2024, FDA lithium label 2018; procedure is synthesis]
  • Example language (illustrative): "Thanks for telling me. Because you're on lithium and a diabetes tablet, this really needs your doctor's eyes on it this week. Can we call the surgery together now?"
  • Watch for: vomiting, confusion, faintness, tremor, rapid breathing or feeling very unwell (urgent medical care); secrecy; escalating restriction. Working: the client is connected to supervision quickly.

5. Handling problems

The sources give little guidance on the psychotherapeutic side; most responses below are [synthesis] built on the safety content they do give.

  • Client insists on going ahead without a doctor. Stay engaged rather than withdrawing; explain specifically why supervision matters for them (their medicines, health conditions), offer to help arrange an appointment, and document your advice. If there are acute warning signs, escalate as for any medical risk. [synthesis; risks from Ede et al. 2026, Rog et al. 2024]
  • Client hopes the diet will replace medication. Validate the wish, restate that KMT is studied as an add-on and that medicine decisions sit with the prescriber, and help the client take the goal to them (B5). [source: Ede et al. 2026; response synthesis]
  • Prescriber is dismissive or no KMT-trained team exists locally. Help the client prepare clear questions and consider a second opinion within their health system; do not become the substitute supervisor. Say honestly that access to trained teams is limited and the standard of expertise is not yet defined. [source: Ede et al. 2026 on undefined standards; synthesis]
  • Overwhelm from the practical load. Break tasks down, mobilise support, and ask the nutrition team whether the plan can be adapted; the consensus stresses tailoring to preferences and long-term sustainability, and notes that less-supported people may need more intensive settings. [source: Ede et al. 2026; synthesis]
  • Non-adherence, lapses and shame. Treat lapses as data; use MI to explore ambivalence; check whether a lapse reflects bingeing after restriction (B2); remind the client of the team's contingency plan and the need for heightened mood monitoring. [source: Rog et al. 2024 on MI/CBT; Ede et al. 2026 on contingency plans; synthesis]
  • Emerging disordered eating. Name it gently, increase screening, inform the prescriber and nutrition team with consent, and consider eating-disorder specialist referral. Do not negotiate food rules yourself. [synthesis; Ede et al. 2026 on anorexia nervosa as a contraindication]
  • Early symptom flare. Distinguish neither alone nor too quickly between "keto flu", physical causes and psychiatric relapse; route to the team, who check hydration, electrolytes, blood pressure and blood sugar; manage risk as usual. Avoid judging benefit too early, as the consensus notes benefits may take weeks to months. [source: Ede et al. 2026; synthesis]
  • Elevated mood interpreted as success. Ask about sleep, spending, speed of thought and risk-taking; report possible hypomania promptly. In one pilot, a participant needed a medication change after a month of elevated mood. [source: Needham et al. 2023; synthesis]
  • Physical warning signs reported in session (vomiting, diarrhoea, tremor, unsteadiness, confusion, fainting, feeling very unwell, especially on lithium or diabetes medicines). Advise same-day contact with the prescriber or urgent care, depending on severity; do not wait for the next session. [source: FDA lithium label 2018; Needham et al. 2023; synthesis]
  • Rupture: client feels you are against the diet, or that you are pushing it. Acknowledge the perception, restate your neutral role (safety and support, not deciding), and repair through collaboration on the client's goals. [synthesis]
  • Family conflict about the diet. With consent, include family in psychoeducation about supervision, early-warning signs and avoiding pressure around food. [synthesis]
  • Influence of online communities or wellness marketing. Explore what the client has read, separate attributed claims (e.g. Palmer's metabolic theory) from what small studies have shown, and help the client bring specific claims to the team. [synthesis; evidence status from Rog et al. 2024 and Ede et al. 2026]
  • Pregnancy or planned pregnancy during therapy. Flag to the prescriber at once; Rog et al. state the diet should not be recommended in pregnancy or when planning it. [source: Rog et al. 2024]
  • Client stops abruptly. Tell the team, monitor closely for mood change, and support the decision without blame. [source: Ede et al. 2026; Needham et al. 2023; synthesis]

Sources

← Previous · IX-103Nutritional psychiatryNext · IX-105 →Omega-3 and other nutrient augmentation